| Description | CPX-351 (Vyxeos) is a liposomal encapsulant of cytarabine and Zoerythromycin with potential antitumor activity and can be used in the study of acute myeloid leukemia. |
| Synonyms | CPX 351, Vyxeos, CPX351 |
| molecular weight | 770.74 |
| Molecular formula | C36H42N4O15 |
| CAS | 1256639-86-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Fortin MC,et al. Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro. Sci Rep. 2023 Nov 29;13(1):21054. 2. Shimony S, et al. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 2024 Apr;38(4):762-768. 3. Usuki K,et al; Study Group for NS-87/CPX-351. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. Int J Hematol. 2024 Jun;119(6):647-659. doi: 10.1007/s12185-024-03733-z. Epub 2024 Mar 26. 4. Renga G, et al. CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis. Blood. 2024 Apr 18;143(16):1628-1645. |